NACDS Board members travelled to Washington, D.C., this week to meet with key members of Congress about the urgency of DIR fee relief. (Front row, left to right) Richard Ashworth, president, operations at Walgreen, Co.; Lynne Fruth, president & chairman of the Board, Fruth Pharmacy; Lori Flees, SVP & DMM Health & Wellness, Sam’s Club (Walmart Inc.); (second row, left to right) Craig Painter, executive chairman of the Board, Kinney Drugs, Inc.; NACDS Chairman Chris Lane, RPh, executive vice president, Wakefern Food Corp./ShopRite; Rick Keyes, president & CEO, Meijer, Inc.; (back row, left to right) Randy Edeker, chairman, CEO and president, Hy-Vee, Inc.; Steven C. Anderson, IOM, CAE, NACDS president and CEO; Kevin Hourican, president, CVS Pharmacy & executive vice president, CVS Health; and Kirk Kaminsky, president, Pharmaceutical Solutions and Services, McKesson, representing Health Mart.
Ten NACDS Board of Directors members met with key members of Congress in Washington, D.C. this week. The meetings focused on conveying the urgent need for direct and indirect remuneration (DIR) fee relief.
The timing was ideal, given that decisions are being made now about drug-pricing legislation.
NACDS Board members with Rep. Kurt Schrader (D-OR), member of the House Energy & Commerce Health Subcommittee.
NACDS Board members with Rep. Dave Loebsack (D-IA), member of the House Energy & Commerce Committee.
NACDS Board members met with Rep. Fred Upton (R-MI), a member of the House Energy & Commerce Health Subcommittee.
NACDS Board members with Sen. James Lankford (R-OK), member of the Senate Finance Committee.
NACDS Board members with Rep. John Shimkus (R-IL), member of the House Energy & Commerce Health Subcommittee.
NACDS Board members with pharmacy champion Rep. Roger Marshall (R-KS)